Roebuck Food Group plc (AIM: RFG),
is pleased to announce its results for the year ended 31 December
2023.
Group Financial Highlights - Continuing
Operations
·
Group revenue decreased by 15% to £26.7m (2022:
£31.4m)
·
Operating profit from continuing operations
declined from £336,000 to a loss of £1,660,000 in the period under
review.
·
The loss for the financial year from continuing
operations amounted to £1,851,000. This compared to a profit of
£156,000 in the prior year.
·
Earnings per share of (5.8)p on continuing
operations (2022: 0.5p).
·
Significantly, net debt has decreased 71% from
£3.44m in 2022 to £1m in 2023. Excluding IFRS 16, which reflects
the lease obligations on Cantwellscourt Farm and Moorhead McGavin
Limited to be classifed as debt, net debt at end 2023 was
zero.
·
Strategic acquisition on 30 November 2023 of
Moorhead and McGavin Limited, a specialty supplier of pules,
cereals, pasta and rice to the food service industry.
Divisional Highlights - Continuing
Operations
£'000
|
Sourcing
|
Dairy
|
Plant Protein
|
|
2023
|
2022
|
2023
|
2022
|
2023
|
2022
|
Revenue
|
24.8
|
29.9
|
1.4
|
1.5
|
0.5
|
-
|
EBITDA
|
(0.2)
|
0.4
|
(0.1)
|
0.5
|
0.2
|
-
|
Operating Profit/(loss)
|
(0.3)
|
0.4
|
(0.4)
|
0.3
|
0.1
|
-
|
Operating Margin
|
(1.21)%
|
1.3%
|
(29)%
|
20%
|
20%
|
-
|
Sourcing Division
Post Brexit, Townview Foods (which
forms the main part of our sourcing division) had to reset.
Management delivered a more diversified business, trading across 41
countries internationally. We are now evolving the business
further. We are in the process of revising the business model,
which will involve changing our sales model and broadening the
product offering, which in turn will give us access to new
customers and new markets. We believe this will provide the
basis of a more durable business model. This transition
has required a significant investment in people which has more than
offset the net profit growth to date.
Sales at our sourcing division
decreased by 17% in 2023, compared with the same period in 2022,
from £29.9m to £24.8m. The board decided to reduce trade to South
Africa due to receivable recovery risks. Sales to South Africa
decreased £4.3m from £5.1m in 2022 to £0.8m in 2023. Operating
profit decreased from £0.4m to a loss of £0.3m.
Chairman's Statement (Continued)
Dairy Division
Notwithstanding a precipitous
decline in dairy product prices, particularly in the second half of
2023, Cantwellscourt Farm managed to generate a small positive
EBITDA before accounting for losses on biological assets.
Reflecting the changes in nitrates rules, stock had to be sold into
a very weak market resulting in an overall loss of £0.4m in the
Diary Division.
Plant Protein And Ingredients Division
Moorhead & McGavin Limited
(M&M) a business that was acquired 30 November 2023 specialises
in supplying pulses, cereals, pasta and rice to the food service
industry. The business delivered sales of £0.54m and an EBITDA of
£0.1m in the first trading month since acquisition.
Outlook
We have largely now reset our key
remaining business from Norish Plc; Townview Foods, Townview
Sourcing and Cantwellscourt Farm. We expect to see improvement in
all businesses as we move through 2024.
Moorhead & McGavin Limited
(M&M), which was acquired 30 November 2023, continues to grow
strongly. We look forward to continue working with the team at
M&M to grow the business both organically and by acquisition. I
would like to thank all at M&M for their commitment and loyalty
to M&M and subsequently Roebuck Food Group, in the period
during and post-acquisition.
Management at Roebuck Food Group
have spent a lot of time looking at acquisition opportunities in
the space defined by the need to feed a growing world population,
with less land, water and with a lower carbon footprint. The
inevitable disruption which will be caused by these seemingly
differing needs will create opportunity. At this juncture we
believe that we can build a business of significant size and scale
over the next number of years in the best interest of all of the
stakeholders of the company. Inevitably this will likely involve
further issuance of equity. It goes without saying that we
remain focused on delivering shareholder value
through efficient capital allocation.
Dividend
The board does not recommend the
payment of a dividend.
On behalf of the board, I would like
to thank the management team and staff for their commitment and
contribution in 2023.
Ted
O'Neill
28
March 2024
Chairman's Statement (Continued)
Sales
Total Group revenue from continuing
operations decreased by 15% to £26.7m (2022: £31.4m). Revenues in
the Product Sourcing division (Townview Foods Ltd and Townview
Sourcing Ltd) decreased by 17% to £24.8m (2022: £29.9m). Revenues
in the Agri division (Cantwellscourt Farm Ltd) decreased by 6.67%
to £1.4m (2022: £1.5m). The newly acquired Plant Protein and
Ingredients division contributed £0.54m to revenues following the
acquisition of Moorhead & McGavin Limited on 30 November
2023.
Gross
(loss)/profit
Gross (loss)/profit from continuing
activities £32k (2022: profit £883k).
Operating
loss/(profit)
Operating loss from continuing
activities increased to £1.66m (2022: profit £0.3m).
Finance expense
(net)
Net Finance expense increased to
£0.14m (2022: £0.12m).
Loss from discontinued
operations
Loss from discontinued operations
£Nil (2022: £1.4m).
Earnings per
share
The basic adjusted earnings per
share from continuing operations decreased to (5.8)p (2022:
0.5p).
Net Debt
The net debt position is £0.98m
(2022: £3.44m).
Share
Capital
£2.5m (before expenses) was raised
during the year by the issue of 18,518,514 new ordinary shares to
fund the acquisition of Moorhead & McGavin Limited. A further
£150,000 (before expenses) representing 1,071,428 new ordinary
shares was issued as part of the purchase consideration for
Moorhead & McGavin Limited.
Financial Review (Continued)
Dividend
The board does not recommend a
payment of a dividend.
Treasury policy and management
The treasury function, which is
managed centrally, handles all Group funding, debt, cash, working
capital and foreign exchange exposures. Group treasury policy
concentrates on the minimisation
of risk in all of the above areas and is
overseen and approved by the Board.
Speculative positions are not taken.
Financial risk
management
The Group's financial instruments
comprise borrowings, cash, and various items, such as trade
receivables, trade payables etc., that arise directly from its
operations. The main purposes of the financial instruments
not arising directly from operations is to raise finance for the
Group's operations.
The Group may enter into derivative
transactions such as interest rate swaps, caps or forward foreign
currency transactions in order to minimise its risks. The
purpose of such transactions is to manage the interest rate and
currency risks arising from the Group's operations and its sources
of finance. No such material transactions were entered into
in either 2023 or 2022.
The main risks arising from the
Group's financial instruments are interest rate risk, liquidity
risk, credit risk and foreign exchange risk. The Group's
policies for managing each of these risks are summarised
below.
Interest rate
risk
The Group finances its operations
through a mixture of retained profits, bank and other borrowings at
both fixed and floating rates of interest and working
capital. The Group determines the level of borrowings at
fixed rates of interest having regard to current market rates and
future trends. At the year-end there are £0.1m at a floating
rate of 7.59% and £1.1m at a fixed rate of 7.3%.
Liquidity
risk
The Group is in a net debt position
of £1m. This is made up of cash of £1.2m, Invoice financing of
£1.1m, term loans of £0.1m and leases of £1m.
Credit risk
The Group's policy is to minimise
exposure to credit risk by performing the appropriate customer due
diligence and monitoring the exposure to credit risk.
Foreign exchange
risk
The Group's policy is to manage
foreign exchange risk which arises principally in the product
sourcing division. The Group does this by mainly purchasing Euros
and US dollars at a fixed rate forward for cross currency
transactions and using this rate in establishing a selling price
for its goods in order to maintain an acceptable margin.
Gerard Murphy
Finance Director
28th March 2024
Consolidated STATEMENT OF COMPREHENSIVE
INCOME
for
the financial year ended 31 December 2023
|
|
|
2023
|
2022
|
|
|
|
£'000
|
£'000
|
|
|
|
|
|
Continuing operations
|
|
|
|
|
Revenue
|
|
|
26,737
|
31,351
|
Cost of sales
|
|
|
(26,769)
|
(30,468)
|
|
|
|
|
|
Gross (loss)/profit
|
|
|
(32)
|
883
|
|
|
|
|
|
Fair value gain on biological
assets
|
|
|
139
|
182
|
Administrative expenses
|
|
|
(1,189)
|
(729)
|
Acquisition and related
costs
|
|
|
(578)
|
-
|
|
|
|
|
|
Operating (loss)/profit from continuing
operations
|
|
|
(1,660)
|
336
|
|
|
|
|
|
Interest received
|
|
|
25
|
9
|
Finance expenses - lease
interest
|
|
|
(28)
|
(28)
|
Finance expenses - interest on bank
loans
|
|
|
(138)
|
(100)
|
|
|
|
|
|
(Loss)/profit on continuing activities before
taxation
|
|
|
(1,801)
|
217
|
|
|
|
|
|
|
|
|
|
|
Income taxes - Corporation
tax
|
|
|
(12)
|
(40)
|
Income taxes - Deferred
tax
|
|
|
(38)
|
(21)
|
|
|
|
|
|
(Loss)/profit for the financial year from continuing
operations
|
|
|
(1,851)
|
156
|
|
|
|
|
|
Loss for the financial year from
discontinued operations
|
|
|
-
|
(1,404)
|
|
|
|
|
|
Loss
for the financial year attributable to
owners of the parent
|
|
|
(1,851)
|
(1,248)
|
|
|
|
|
|
Other comprehensive (expense)/
income
|
|
|
(26)
|
169
|
Total comprehensive loss for the financial year attributable
to owners of the parent
|
|
|
(1,877)
|
(1,079)
|
CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME
|
|
|
|
|
|
for
the financial year ended 31 December 2023
(continued)
|
|
|
|
|
|
|
|
|
2023
|
2022
|
|
|
|
|
|
(Loss)/earnings per share expressed in pence per
share:
|
|
|
|
|
From continuing operations
- basic
|
|
|
(5.8)p
|
0.5p
|
- diluted
|
|
|
(5.8)p
|
0.5p
|
|
|
|
|
|
|
|
|
|
|
From discontinued
operations
- basic
|
|
|
-p
|
(4.7)p
|
- diluted
|
|
|
-p
|
(4.7)p
|
|
|
|
|
|
Consolidated Statement of financial position
at
31 December 2023
|
|
|
2023
|
2022
|
|
|
|
£'000
|
£'000
|
Non-current
assets
|
|
|
|
|
Goodwill
|
|
|
2,338
|
2,338
|
Intangible assets
|
|
|
600
|
-
|
Property, plant and equipment
|
|
|
3,048
|
2,162
|
Biological assets
|
|
|
642
|
884
|
|
|
|
6,628
|
5,384
|
Current
assets
|
|
|
|
|
Trade and other receivables
|
|
|
3,649
|
7,223
|
Inventories
|
|
|
1,044
|
316
|
Cash and cash equivalents
|
|
|
1,186
|
1,491
|
|
|
|
5,879
|
9,030
|
|
|
|
|
|
TOTAL
ASSETS
|
|
|
12,507
|
14,414
|
|
|
|
|
|
Equity
attributable to owners of the parent
|
|
|
|
|
Share capital
|
|
|
990
|
564
|
Share premium
|
|
|
2,094
|
-
|
Other reserves
|
|
|
(94)
|
(68)
|
Retained earnings
|
|
|
3,353
|
5,204
|
TOTAL
EQUITY
|
|
|
6,343
|
5,700
|
|
|
|
|
|
Non-current
liabilities
|
|
|
|
|
Borrowings
|
|
|
932
|
1,016
|
Deferred tax
|
|
|
168
|
58
|
|
|
|
1,100
|
1,074
|
Current
liabilities
|
|
|
|
|
Trade and other payables
|
|
|
3,826
|
3,427
|
Liabilities - discontinued operations
|
|
|
-
|
298
|
Borrowings
|
|
|
1,238
|
3,915
|
|
|
|
5,064
|
7,640
|
|
|
|
|
|
TOTAL EQUITY
AND LIABILITIES
|
|
|
12,507
|
14,414
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statement of Changes in Equity
For the financial year ended 31 December
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
|
Share
|
Other
|
Retained
|
|
|
capital
|
Premium
|
Reserves
|
Earnings
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
At 1
January 2022
|
564
|
-
|
(237)
|
6,452
|
6,779
|
Loss for the financial
year
|
-
|
-
|
-
|
(1,248)
|
(1,248)
|
Foreign exchange gain
|
-
|
-
|
169
|
-
|
169
|
Total comprehensive income for the financial
year
|
-
|
-
|
169
|
(1,248)
|
(1,079)
|
Equity dividends paid
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
Transactions with owners
|
-
|
-
|
-
|
-
|
-
|
At
31 December 2022
|
564
|
-
|
(68)
|
5,204
|
5,700
|
|
|
|
|
|
|
Loss for the financial
year
|
-
|
-
|
-
|
(1,851)
|
(1,851)
|
Foreign exchange loss
|
-
|
-
|
(26)
|
|
(26)
|
Total comprehensive income for the financial
year
|
-
|
-
|
(26)
|
(1,851)
|
(1,877)
|
Issue of share capital
|
426
|
2,224
|
-
|
-
|
2,650
|
Share issue costs
|
-
|
(130)
|
-
|
-
|
(130)
|
Transactions with owners
|
426
|
2,094
|
(26)
|
(1,851)
|
643
|
At
31 December 2023
|
990
|
2,094
|
(94)
|
3,353
|
6,343
|
Consolidated Cash Flow Statement
for the
financial year ended 31 December 2023
|
|
2023
|
2022
|
|
|
£'000
|
£'000
|
Cash flow from
operating activities
|
|
|
|
(Loss)/profit on continuing activities before
taxation
|
|
(1,801)
|
217
|
Gain on change in fair value of biological
assets
|
|
(139)
|
(182)
|
Biological assets disposal
|
|
91
|
117
|
Foreign exchange gain
|
|
(382)
|
(201)
|
Loss on discontinued activities
|
|
-
|
(1,404)
|
Finance expenses
|
|
166
|
128
|
Finance income
|
|
-
|
(9)
|
Bad debt expense
|
|
15
|
41
|
Taxation charge
|
|
(12)
|
(40)
|
Impairment - Intangible asset
|
|
-
|
665
|
Depreciation - property, plant and
equipment
|
|
187
|
191
|
Operating cash
flows before changes in working capital
|
|
(1,875)
|
(477)
|
|
|
|
|
Changes in
working capital and provisions:
|
|
|
|
Increase/ (decrease) in inventories
|
|
66
|
(218)
|
Increase/ (decrease) in trade and other
receivables
|
|
4,826
|
(3,223)
|
Decrease in current liabilities held for
sale
|
|
-
|
(1,571)
|
(Decrease)/ increase in payables
|
|
(1,212)
|
848
|
Taxation paid
|
|
(3)
|
(25)
|
Net cash
from/(used in) from operating activities
|
|
3,677
|
(4,189)
|
Cash flow from
investing activities
|
|
|
|
Payments to acquire subsidiary
undertaking
|
|
(2,075)
|
-
|
Cash acquired as part of acquisition
|
|
299
|
-
|
Purchase of property, plant and
equipment
|
|
(63)
|
(62)
|
Proceeds from sale of biological
assets
|
|
272
|
149
|
Net cash
used/generated from investing activities
|
|
(1,567)
|
87
|
Invoice finance utilised
|
|
(2,805)
|
1,649
|
Finance lease capital repayments
|
|
(69)
|
(91)
|
Term loan repayments
|
|
(36)
|
(31)
|
Net proceeds from issue of share
capital
|
|
2,370
|
-
|
Net cash
used/generated from financing activities
|
|
(540)
|
1,527
|
|
|
|
|
Net decrease in
cash and cash equivalents
|
|
(305)
|
(3,052)
|
Cash and cash equivalents beginning of the
financial year
|
|
1,491
|
4,543
|
Cash and cash equivalents end of the financial
year
|
|
1,186
|
1,491
|